Payment overview · 2025
General Payments
$247.26
11 reported records · 8 companies
Healthcare provider profile · identity verified
Douglas George Kelling, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Pulmonary Disease · CONCORD, NC · NPI 1396717708
Verified facts
What the public records show
CMS Open Payments records show Douglas George Kelling, MD received $247.26 in general payments during 2025 across 11 reported records.
IDORSIA PHARMACEUTICALS US INC accounted for 21.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Trelegy Ellipta.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 251 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 466 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUCALA as an associated drug or biological on 100127 records involving 16970 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nucala by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 191 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 251 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 174 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 141 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 466 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| IDORSIA PHARMACEUTICALS US INC | Unresolved — no canonical attribution shown | $52.48 | 21.2% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $41.77 | 16.9% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $40.28 | 16.3% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $38.88 | 15.7% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $21.67 | 8.8% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $21.05 | 8.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.05 | 6.9% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.08 | 5.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $194.78 | 10 |
| Education | $52.48 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Tryvio Normalized: tryvio |
Drug | IDORSIA PHARMACEUTICALS US INC | $52.48 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $41.77 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $40.28 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $38.88 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $38.88 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $21.67 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $21.05 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.05 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $17.05 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.08 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 466 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 251 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 174 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 191 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
251 | 47 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
466 | 78 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | NUCALA open payments reported associated product |
CMS Open Payments — General Payments 100127 supporting records · 16970 recipient NPIs · example record 1190332378 |
Nucala · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
191 | 55 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
251 | 47 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
174 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
141 | 23 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
466 | 78 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1022 | 242 |
| Amlodipine Besylate | Amlodipine Besylate | 868 | 213 |
| Omeprazole | Omeprazole | 672 | 144 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 572 | 136 |
| Levothyroxine Sodium | Levothyroxine Sodium | 528 | 112 |
| Losartan Potassium | Losartan Potassium | 480 | 118 |
| Eliquis | Apixaban | 466 | 78 |
| Lisinopril | Lisinopril | 437 | 108 |
| Potassium Chloride | Potassium Chloride | 434 | 99 |
| Ezetimibe | Ezetimibe | 379 | 95 |
| Furosemide | Furosemide | 362 | 97 |
| Metformin Hcl | Metformin Hcl | 357 | 85 |
| Gabapentin | Gabapentin | 348 | 87 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 343 | 92 |
| Hydralazine Hcl | Hydralazine Hcl | 286 | 65 |
| Montelukast Sodium | Montelukast Sodium | 284 | 51 |
| Metoprolol Tartrate | Metoprolol Tartrate | 272 | 64 |
| Duloxetine Hcl | Duloxetine Hcl | 267 | 59 |
| Mirtazapine | Mirtazapine | 253 | 55 |
| Jardiance | Empagliflozin | 251 | 47 |
| Pravastatin Sodium | Pravastatin Sodium | 248 | 64 |
| Metoprolol Succinate | Metoprolol Succinate | 235 | 52 |
| Ozempic | Semaglutide | 225 | 41 |
| Pantoprazole Sodium | Pantoprazole Sodium | 213 | 53 |
| Metformin Hcl Er | Metformin Hcl | 196 | 44 |
| Trazodone Hcl | Trazodone Hcl | 196 | 46 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 191 | 55 |
| Clopidogrel | Clopidogrel Bisulfate | 186 | 42 |
| Allopurinol | Allopurinol | 179 | 39 |
| Fluticasone Propionate | Fluticasone Propionate | 179 | 59 |
| Chlorthalidone | Chlorthalidone | 178 | 42 |
| Buspirone Hcl | Buspirone Hcl | 177 | 34 |
| Vascepa | Icosapent Ethyl | 177 | 28 |
| Simvastatin | Simvastatin | 175 | 38 |
| Mounjaro | Tirzepatide | 174 | 31 |
| Warfarin Sodium | Warfarin Sodium | 164 | 39 |
| Tizanidine Hcl | Tizanidine Hcl | 157 | 33 |
| Spironolactone | Spironolactone | 143 | 36 |
| Trulicity | Dulaglutide | 141 | 23 |
| Carvedilol | Carvedilol | 139 | 39 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 130 | 59 |
| Sertraline Hcl | Sertraline Hcl | 125 | 34 |
| Symbicort | Budesonide/Formoterol Fumarate | 123 | 30 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 121 | 26 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 119 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 111 | 29 |
| Xarelto | Rivaroxaban | 103 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 98 | 24 |
| Farxiga | Dapagliflozin Propanediol | 91 | 15 |
| Tramadol Hcl | Tramadol Hcl | 91 | 19 |
| Prednisone | Prednisone | 90 | 47 |
| Methylprednisolone | Methylprednisolone | 89 | 71 |
| Famotidine | Famotidine | 88 | 21 |
| Donepezil Hcl | Donepezil Hcl | 86 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 85 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 83 | 19 |
| Incruse Ellipta | Umeclidinium Bromide | 75 | 13 |
| Bupropion Xl | Bupropion Hcl | 74 | 17 |
| Pregabalin | Pregabalin | 74 | 15 |
| Tresiba Flextouch U-100 | Insulin Degludec | 72 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 71 | 17 |
| Repatha Sureclick | Evolocumab | 70 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 70 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 68 | 19 |
| Telmisartan | Telmisartan | 64 | 12 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 63 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 61 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 58 | 13 |
| Icosapent Ethyl | Icosapent Ethyl | 58 | 15 |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 57 | 11 |
| Candesartan Cilexetil | Candesartan Cilexetil | 57 | 12 |
| Torsemide | Torsemide | 56 | 22 |
| Ropinirole Hcl | Ropinirole Hcl | 55 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 54 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 54 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 54 | 43 |
| Ipratropium Bromide | Ipratropium Bromide | 53 | 19 |
| Felodipine Er | Felodipine | 52 | 11 |
| Novolog Flexpen | Insulin Aspart | 52 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 50 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 48 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 47 | 12 |
| Ondansetron Odt | Ondansetron | 47 | 23 |
| Benazepril Hcl | Benazepril Hcl | 46 | suppressed |
| Klor-Con M20 | Potassium Chloride | 46 | 18 |
| Dexlansoprazole Dr | Dexlansoprazole | 44 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 43 | 12 |
| Finasteride | Finasteride | 41 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 41 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 41 | 12 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 40 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 40 | 22 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 39 | 30 |
| Clonazepam | Clonazepam | 38 | suppressed |
| Nitroglycerin | Nitroglycerin | 38 | 17 |
| Humalog Kwikpen U-100 | Insulin Lispro | 36 | 18 |
| Diltiazem 24hr Er | Diltiazem Hcl | 35 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 35 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 35 | suppressed |
| Temazepam | Temazepam | 34 | suppressed |
| Easy Comfort Pen Needle | Pen Needle, Diabetic | 33 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 33 | suppressed |
| Meloxicam | Meloxicam | 32 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 31 | suppressed |
| Praluent Pen | Alirocumab | 31 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 30 | suppressed |
| Atenolol | Atenolol | 30 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 30 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 30 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | suppressed |
| Valsartan | Valsartan | 30 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 27 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 27 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Fluconazole | Fluconazole | 26 | 16 |
| Lansoprazole | Lansoprazole | 26 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 26 | 11 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Entresto | Sacubitril/Valsartan | 24 | suppressed |
| Januvia | Sitagliptin Phosphate | 24 | suppressed |
| Livalo | Pitavastatin Calcium | 24 | suppressed |
| Lovastatin | Lovastatin | 24 | suppressed |
| Mupirocin | Mupirocin | 24 | 20 |
| Alprazolam | Alprazolam | 23 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 22 | suppressed |
| Cephalexin | Cephalexin | 22 | 16 |
| Theophylline Er | Theophylline Anhydrous | 22 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 21 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 21 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 21 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 20 | suppressed |
| Epinephrine | Epinephrine | 20 | 14 |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 20 | suppressed |
| Lactulose | Lactulose | 20 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 20 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Clonidine | Clonidine | 19 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | 11 |
| Midodrine Hcl | Midodrine Hcl | 19 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 19 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Humalog | Insulin Lispro | 18 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 18 | suppressed |
| Lorazepam | Lorazepam | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 18 | suppressed |
| Sotalol | Sotalol Hcl | 18 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 18 | suppressed |
| Xolair | Omalizumab | 18 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 16 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Dupixent Pen | Dupilumab | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Glassia | Alpha-1-Proteinase Inhibitor | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Invokana | Canagliflozin | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 13 |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Tradjenta | Linagliptin | 14 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Xifaxan | Rifaximin | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | suppressed |
| Dupixent Syringe | Dupilumab | 12 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Nucala | Mepolizumab | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Advocate Pen Needles | Pen Needle, Diabetic | 11 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 11 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $247.26 · 11 records | IDORSIA PHARMACEUTICALS US INC | AREXVY, ELIQUIS, JARDIANCE, Kerendia, MOUNJARO, NURTEC ODT, Omnipod, TRELEGY ELLIPTA, Tryvio, ZAVZPRET | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error